Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database
Tomohiko Kanaoka,Hiromichi Wakui,Yuichiro Yano,Hajime Nagasu,Hiroshi Kanegae,Masaomi Nangaku,Yosuke Hirakawa,Naoki Nakagawa,Jun Wada,Kazuhiko Tsuruya,Toshiaki Nakano,Shoichi Maruyama,Takashi Wada,Masaaki Konishi,Takanori Nagahiro,Kunihiro Yamagata,Ichiei Narita,Motoko Yanagita,Yoshio Terada,Shinichi Araki,Masanori Emoto,Hirokazu Okada,Yoshitaka Isaka,Yusuke Suzuki,Takashi Yokoo,Hiromi Kataoka,Eiichiro Kanda,Naoki Kashihara,Kouichi Tamura,for the J‐CKD‐DB investigators
DOI: https://doi.org/10.1111/dom.15611
2024-05-10
Diabetes Obesity and Metabolism
Abstract:Aim Sodium‐glucose cotransporter 2 (SGLT2) inhibitors often cause a transient decrease in glomerular filtration rate (GFR) shortly after the initiation, referred to as the 'initial drop'. However, the clinical significance of this initial drop in real‐world practice remains unclear. Materials and Methods Using the nationwide Japan Chronic Kidney Disease Database, we examined factors that affected the initial drop, in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). We also evaluated the effects of the initial drop on a composite kidney outcome (a decline in GFR of ≥50% or progression to end‐stage kidney disease). Results Data from 2053 patients with CKD and T2DM newly prescribed an SGLT2 inhibitor were analysed. The follow‐up period after SGLT2 inhibitor administration was 1015 days (interquartile range: 532, 1678). Multivariate linear regression models revealed that the concomitant use of the renin‐angiotensin system inhibitors and diuretics, urinary protein levels ≥2+, and changes in GFR before the initiation of the SGLT2 inhibitor were associated with a larger initial GFR decline (β = −0.609, p = .039; β = −2.298, p
endocrinology & metabolism